180 related articles for article (PubMed ID: 3092389)
21. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
[TBL] [Abstract][Full Text] [Related]
22. Plasminogen activator inhibitor activity in bacterial infection.
Páramo JA; Fernández Diaz FJ; Rocha E
Thromb Haemost; 1988 Jun; 59(3):451-4. PubMed ID: 3142082
[TBL] [Abstract][Full Text] [Related]
23. Determination of plasminogen activator inhibitor in plasma using t-PA and a chromogenic single-point poly-D-lysine stimulated assay.
Eriksson E; Rånby M; Gyzander E; Risberg B
Thromb Res; 1988 Apr; 50(1):91-101. PubMed ID: 3135638
[TBL] [Abstract][Full Text] [Related]
24. Plasminogen activator inhibitor 1: development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation.
Kruithof EK; Nicolosa G; Bachmann F
Blood; 1987 Nov; 70(5):1645-53. PubMed ID: 3117137
[TBL] [Abstract][Full Text] [Related]
25. Modulation of rapid plasminogen activator inhibitor in plasma by stanozolol.
Verheijen JH; Rijken DC; Chang GT; Preston FE; Kluft C
Thromb Haemost; 1984 Jul; 51(3):396-7. PubMed ID: 6437007
[TBL] [Abstract][Full Text] [Related]
26. Plasminogen activator inhibitor-1 is the primary inhibitor of tissue-type plasminogen activator in pregnancy plasma.
Jørgensen M; Philips M; Thorsen S; Selmer J; Zeuthen J
Thromb Haemost; 1987 Oct; 58(3):872-8. PubMed ID: 3124286
[TBL] [Abstract][Full Text] [Related]
27. Purification of a specific placental plasminogen activator inhibitor by monoclonal antibody and its complex formation with plasminogen activator.
Astedt B; Lecander I; Brodin T; Lundblad A; Löw K
Thromb Haemost; 1985 Feb; 53(1):122-5. PubMed ID: 3922076
[TBL] [Abstract][Full Text] [Related]
28. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation.
Colucci M; Paramo JA; Collen D
J Clin Invest; 1985 Mar; 75(3):818-24. PubMed ID: 3920245
[TBL] [Abstract][Full Text] [Related]
29. Renal and hepatic handling of endogenous tissue-type plasminogen activator (t-PA) and its inhibitor in man.
Brommer EJ; Derkx FH; Schalekamp MA; Dooijewaard G; vd Klaauw MM
Thromb Haemost; 1988 Jun; 59(3):404-11. PubMed ID: 3142078
[TBL] [Abstract][Full Text] [Related]
30. Increase in plasma concentration of plasminogen activator inhibitor, fibrinogen, von Willebrand factor, factor VIII:C and in erythrocyte sedimentation rate with age.
Aillaud MF; Pignol F; Alessi MC; Harle JR; Escande M; Mongin M; Juhan-Vague I
Thromb Haemost; 1986 Jun; 55(3):330-2. PubMed ID: 3092390
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of fibrinolytic capacity by a combined assay system for tissue-type plasminogen activator antigen and function using monoclonal anti-tissue-type plasminogen activator antibodies.
Wojta J; Turcu L; Wagner OF; Korninger C; Binder BR
J Lab Clin Med; 1987 Jun; 109(6):665-71. PubMed ID: 3108431
[TBL] [Abstract][Full Text] [Related]
32. Fibrinolytic and haemostatic responses to desamino-D-arginine vasopressin (DDAVP) administered by intravenous and subcutaneous routes in healthy subjects.
MacGregor IR; Roberts EM; Prowse CV; Broomhead AF; Ozolins M; Litka P
Thromb Haemost; 1988 Feb; 59(1):34-9. PubMed ID: 3129807
[TBL] [Abstract][Full Text] [Related]
33. Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states.
Kruithof EK; Gudinchet A; Bachmann F
Thromb Haemost; 1988 Feb; 59(1):7-12. PubMed ID: 3129809
[TBL] [Abstract][Full Text] [Related]
34. Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
Thromb Haemost; 1988 Oct; 60(2):247-50. PubMed ID: 3146141
[TBL] [Abstract][Full Text] [Related]
35. Impaired fibrinolysis in obstructive jaundice--evidence from clinical and experimental studies.
Colucci M; Altomare DF; Chetta G; Triggiani R; Cavallo LG; Semeraro N
Thromb Haemost; 1988 Aug; 60(1):25-9. PubMed ID: 3142090
[TBL] [Abstract][Full Text] [Related]
36. Increased plasminogen activator inhibition levels in malignancy.
de Jong E; Knot EA; Piket D; Iburg AH; Rijken DC; Veenhof KH; Dooijewaard G; ten Cate JW
Thromb Haemost; 1987 Apr; 57(2):140-3. PubMed ID: 3110994
[TBL] [Abstract][Full Text] [Related]
37. Tissue plasminogen activator inhibitor in human plasma: development of a functional assay system and demonstration of a correlating Mr = 50,000 antiactivator.
Korninger C; Wagner O; Binder BR
J Lab Clin Med; 1985 Jun; 105(6):718-24. PubMed ID: 3923146
[TBL] [Abstract][Full Text] [Related]
38. Release pattern of the vascular plasminogen activator and its inhibitor in human postvenous occlusion plasma as assessed by a spectrophotometric solid-phase fibrin-tPA activity assay.
Anglés-Cano E; Boutière B; Arnoux D; Masson C; Contant G; Benchimol P; Sampol J
Thromb Haemost; 1987 Oct; 58(3):843-9. PubMed ID: 3124285
[TBL] [Abstract][Full Text] [Related]
39. [Changes in plasma tissue plasminogen activator and plasminogen activator inhibitor in acute myocardial infarction and its clinical significance].
Jia HY; Chen HZ; Pu SY
Zhonghua Xin Xue Guan Bing Za Zhi; 1988 Aug; 16(4):214-6, 254. PubMed ID: 3147887
[No Abstract] [Full Text] [Related]
40. Increased plasma levels of urokinase-type plasminogen activator with endometrial and cervical cancer.
Koelbl H; Kirchheimer JC; Tatra G; Christ G; Binder BR
Obstet Gynecol; 1988 Aug; 72(2):252-6. PubMed ID: 3134631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
